Merck & Co. Company Profile (NYSE:MRK)

About Merck & Co. (NYSE:MRK)

Merck & Co. logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:MRK
  • CUSIP: 58933Y10
  • Web:
  • Market Cap: $177.9 billion
  • Outstanding Shares: 2,735,164,000
Average Prices:
  • 50 Day Moving Avg: $63.23
  • 200 Day Moving Avg: $62.88
  • 52 Week Range: $55.10 - $66.80
  • Trailing P/E Ratio: 41.45
  • Foreward P/E Ratio: 15.56
  • P/E Growth: 2.81
Sales & Book Value:
  • Annual Revenue: $39.93 billion
  • Price / Sales: 4.46
  • Book Value: $14.54 per share
  • Price / Book: 4.47
  • Annual Dividend: $1.88
  • Dividend Yield: 2.9%
  • EBIDTA: $15.16 billion
  • Net Margins: 14.30%
  • Return on Equity: 24.08%
  • Return on Assets: 10.77%
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 1.89%
  • Quick Ratio: 1.56%
  • Average Volume: 9.03 million shs.
  • Beta: 0.79
  • Short Ratio: 1.87

Frequently Asked Questions for Merck & Co. (NYSE:MRK)

What is Merck & Co.'s stock symbol?

Merck & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co. pay dividends? What is the dividend yield for Merck & Co.?

Merck & Co. announced a quarterly dividend on Tuesday, May 23rd. Stockholders of record on Thursday, June 15th will be paid a dividend of $0.47 per share on Monday, July 10th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date of this dividend is Tuesday, June 13th. View Merck & Co.'s Dividend History.

How were Merck & Co.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.88 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.83 by $0.05. The company earned $9.43 billion during the quarter, compared to analysts' expectations of $9.25 billion. Merck & Co. had a net margin of 14.30% and a return on equity of 24.08%. The firm's revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.89 earnings per share. View Merck & Co.'s Earnings History.

When will Merck & Co. make its next earnings announcement?

Merck & Co. is scheduled to release their next quarterly earnings announcement on Friday, July, 28th 2017. View Earnings Estimates for Merck & Co..

What guidance has Merck & Co. issued on next quarter's earnings?

Merck & Co. issued an update on its FY17 earnings guidance on Tuesday, May, 2nd. The company provided EPS guidance of $3.76-3.88 for the period, compared to the Thomson Reuters consensus estimate of $3.81. The company issued revenue guidance of $39.1-40.3 billion, compared to the consensus revenue estimate of $39.93 billion.

Where is Merck & Co.'s stock going? Where will Merck & Co.'s stock price be in 2017?

19 brokers have issued 12-month price objectives for Merck & Co.'s shares. Their predictions range from $51.00 to $80.00. On average, they expect Merck & Co.'s stock price to reach $68.24 in the next twelve months. View Analyst Ratings for Merck & Co..

What are analysts saying about Merck & Co. stock?

Here are some recent quotes from research analysts about Merck & Co. stock:

  • 1. According to Zacks Investment Research, "Merck’s beat estimates for both earnings and sales in the first quarter of 2017 and also raised its 2017 guidance. Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products like Keytruda and Zepatier should continue to contribute meaningfully to the top line.  Keytruda uptake in first line lung cancer indication and potential label expansion - with FDA action pending on multiple regulatory applications - are catalysts for the stock in 2017. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. Merck’s shares surpassed the large-cap pharma industry in the past one year. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern." (5/25/2017)
  • 2. BMO Capital Markets analysts commented, "Although expectations for EPOCH were low, we were looking for an efficacy signal in mild patients, which would have increased expectations for the APECS study. Merck's press release does not provide details regarding subgroup analysis in mild patients; however, the language suggests little to no efficacy. This lowers our probability of success for APECS from 50% to 25%, Verubecestat risk-adjusted sales from ~$5Bn in 2026 to ~$2.5Bn, and our valuation from $72 to $70. However, investors should not give up on Verubecestat; APECS has a higher chance of success." (2/15/2017)
  • 3. Jefferies Group LLC analysts commented, "Our Underperform rating is predicated on under-appreciated margin pressure in the base business as well as over-optimistic expectations for Keytruda." (1/12/2017)

Are investors shorting Merck & Co.?

Merck & Co. saw a increase in short interest in May. As of May 15th, there was short interest totalling 18,464,887 shares, an increase of 22.5% from the April 28th total of 15,072,688 shares. Based on an average daily trading volume, of 10,981,725 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.7% of the company's stock are short sold.

Who are some of Merck & Co.'s key competitors?

Who owns Merck & Co. stock?

Merck & Co.'s stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.95%), BlackRock Inc. (6.67%), State Street Corp (4.48%), Wellington Management Group LLP (4.23%), Bank of New York Mellon Corp (1.57%) and Geode Capital Management LLC (1.00%). Company insiders that own Merck & Co. stock include Adam H Schechter, Adele D Ambrose, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Peter C Wendell, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co..

Who sold Merck & Co. stock? Who is selling Merck & Co. stock?

Merck & Co.'s stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Wellington Management Group LLP, State Street Corp, Bank of New York Mellon Corp, Barrow Hanley Mewhinney & Strauss LLC, ACR Alpine Capital Research LLC, Parametric Portfolio Associates LLC and Credit Agricole S A. Company insiders that have sold Merck & Co. stock in the last year include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co..

Who bought Merck & Co. stock? Who is buying Merck & Co. stock?

Merck & Co.'s stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., Bank of Montreal Can, Canada Pension Plan Investment Board, Swiss National Bank, UBS Asset Management Americas Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Merck & Co..

How do I buy Merck & Co. stock?

Shares of Merck & Co. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merck & Co. stock cost?

One share of Merck & Co. stock can currently be purchased for approximately $65.04.

Analyst Ratings

Consensus Ratings for Merck & Co. (NYSE:MRK) (?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.42)
Consensus Price Target: $68.24 (4.91% upside)

Analysts' Ratings History for Merck & Co. (NYSE:MRK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017Jefferies Group LLCReiterated RatingSell$51.00LowView Rating Details
5/11/2017JPMorgan Chase & Co.Boost Price TargetOverweight$74.00 -> $76.00MediumView Rating Details
5/11/2017BMO Capital MarketsBoost Price TargetOutperform$68.00 -> $70.00MediumView Rating Details
5/11/2017Cowen and CompanyReiterated RatingMarket Perform$68.00 -> $70.00MediumView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
2/24/2017Sanford C. BernsteinReiterated RatingMarket PerformN/AView Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
1/12/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$72.00N/AView Rating Details
1/12/2017Morgan StanleyUpgradeEqual Weight -> Overweight$65.00 -> $71.00N/AView Rating Details
1/12/2017GuggenheimUpgradeNeutral -> Buy$61.63 -> $70.00N/AView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 -> $80.00N/AView Rating Details
10/13/2016Bank of America CorpUpgradeNeutral -> Buy$57.00 -> $70.00N/AView Rating Details
10/12/2016Barclays PLCReiterated RatingOverweightN/AView Rating Details
9/11/2016Berenberg BankReiterated RatingHold$62.00N/AView Rating Details
8/10/2016Citigroup IncReiterated RatingNeutral$65.00N/AView Rating Details
8/8/2016Deutsche Bank AGBoost Price TargetHold$58.00 -> $59.00N/AView Rating Details
8/7/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$62.00 -> $73.00N/AView Rating Details
6/8/2016Goldman Sachs Group IncReiterated RatingNeutral$60.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Merck & Co. (NYSE:MRK)
Earnings by Quarter for Merck & Co. (NYSE:MRK)
Earnings History by Quarter for Merck & Co. (NYSE:MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017$0.83$0.88$9.25 billion$9.43 billionViewListenView Earnings Details
2/2/2017Q416$0.89$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.85$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.81$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merck & Co. (NYSE:MRK)
2017 EPS Consensus Estimate: $3.80
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.85$0.85$0.85
Q2 20172$0.89$0.93$0.91
Q3 20172$1.00$1.03$1.02
Q4 20172$1.00$1.05$1.03
(Data provided by Zacks Investment Research)


Current Dividend Information for Merck & Co. (NYSE:MRK)
Next Dividend:7/10/2017
Annual Dividend:$1.88
Dividend Yield:2.89%
Dividend Growth:2.30% (3 Year Average)
Payout Ratio:92.61% (Trailing 12 Months of Earnings)
48.96% (Based on This Year's Estimates)
44.98% (Based on Next Year's Estimates)
Track Record:5 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Merck & Co. (NYSE:MRK)

Dividend History by Quarter for Merck & Co. (NYSE:MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Merck & Co. (NYSE:MRK)
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 74.10%
Insider Trades by Quarter for Merck & Co. (NYSE:MRK)
Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)
Insider Trades by Quarter for Merck & Co. (NYSE:MRK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017C Robert KidderDirectorSell5,000$63.54$317,700.00View SEC Filing  
4/3/2017Adam H SchechterEVPSell53,850$63.48$3,418,398.00View SEC Filing  
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.00View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.00View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.00View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.46View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.00View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.00View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Merck & Co. (NYSE:MRK)
Latest Headlines for Merck & Co. (NYSE:MRK)
DateHeadline logoMerck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau - May 26 at 4:20 AM logoBlog Coverage Merck's KEYTRUDA Becomes First Cancer Drug to be Approved by FDA Based on a Common Biomarker Instead of the Location of the Tumor - May 26 at 4:20 AM logoPerformance of Merck’s Animal Health Segment in 1Q17 - May 26 at 4:19 AM logoOptum and Merck Collaborate to Advance Value-Based Contracting of Pharmaceuticals - May 26 at 4:19 AM logoMerck & Co. Sees Unusually Large Options Volume (MRK) - May 25 at 1:00 PM logoZacks Investment Research Lowers Merck & Co., Inc. (MRK) to Hold - May 25 at 10:08 AM logoMerck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers - May 24 at 6:43 PM logoMerck & Co.'s (MRK) Sell Rating Reaffirmed at Jefferies Group LLC - May 24 at 2:38 PM logoFDA Approves Merck’s Keytruda to Treat Cancers With Genetic Defects - May 24 at 10:37 AM logo1Q17 Performance of Keytruda, Merck’s Blockbuster Drug - May 24 at 10:37 AM logoMerck Announces Third-Quarter 2017 Dividend - May 23 at 6:11 PM logoThe FDA just took an entirely new approach to approving a cancer drug - May 23 at 6:11 PM logoFDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects - May 23 at 6:11 PM logoFDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer - May 23 at 6:11 PM logoMerck Presents Phase II Data on Chronic Cough Candidate - May 23 at 6:11 PM logoFDA clears Merck's Keytruda based on cancer genetics, not location - May 23 at 6:11 PM logoMerck & Co., Inc. (MRK) Announces Quarterly Dividend of $0.47 - May 23 at 3:16 PM logoWhat to Expect From Merck at ASCO - May 23 at 10:24 AM logoFDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Recurrent or Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - May 23 at 10:23 AM logoUK competition watchdog accuses Merck of obstructing biosimilars - May 23 at 10:23 AM logoA Close Look at Merck & Co.’s Valuation after 1Q17 Earnings - May 23 at 10:23 AM logoWhy Merck & Co. Continued to Grow in 1Q17 - May 23 at 10:23 AM logoMerck's HIV Drug Gets Positive CHMP Opinion for Higher Dose - May 22 at 5:57 PM logoMerck's MK-7264 successful in mid-stage chronic cough study - May 22 at 5:57 PM logoMerck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough - May 22 at 5:57 PM logoMerck's HIV Drug Gets Positive CHMP Opinion for Higher Dose - May 22 at 10:04 AM logoMerck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings? - May 22 at 10:04 AM logoMerck's (MRK) Keytruda Gets FDA Nod for Two New Indications - Nasdaq - May 20 at 8:36 AM logoMerck & Co., Inc. (MRK) Receives Average Recommendation of "Hold" from Analysts - May 19 at 11:06 PM logoMerck (MRK) Says FDA Approves KEYTRUDA for Two New Indications fo Types of Bladder Cancer - May 19 at 7:04 PM logoETFs with exposure to Merck & Co., Inc. : May 19, 2017 - May 19 at 7:04 PM logoMerck & Co., Inc. :MRK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 - May 19 at 11:17 AM logoFDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer - May 19 at 11:17 AM logoMerck's Keytruda gets two bladder cancer approvals from FDA - May 19 at 11:17 AM logoUS Market Indexes Higher on Thursday - May 19 at 11:17 AM logoMerck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union - May 19 at 11:17 AM logoMerck's (MRK) Keytruda Gets FDA Nod for Two New Indications - May 19 at 11:17 AM logoMerck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings - May 18 at 8:21 AM logoMerck KGaA CFO Believes in Value Based Pricing - May 18 at 8:21 AM logoWhat to watch at ASCO cancer conference - May 18 at 8:21 AM logoVetr Inc. Lowers Merck & Co., Inc. (MRK) to Buy - May 18 at 12:56 AM logoMerck (MRK) Says Data for KEYTRUDA Across 16 Types of Cancer to Be Presented at ASCO - May 17 at 11:38 PM logoData for KEYTRUDA® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting - May 17 at 6:36 PM logoMerck says test shows Keytruda improves survival for bladder cancer patients - May 17 at 6:36 PM logoZacks: Analysts Anticipate Merck & Co., Inc. (MRK) Will Post Quarterly Sales of $9.67 Billion - May 17 at 12:00 PM logo5 Reasons Why Merck (MRK) is a Good Stock to Buy Now - May 17 at 9:11 AM logoMerck, Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case - May 16 at 11:25 PM logoMerck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the American Diabetes Association - May 16 at 10:26 AM logoDrug Makers Stocks Under Scanner -- Alliqua BioMedical, AbbVie, Johnson & Johnson, and Merck - May 15 at 10:20 AM logoZacks: Brokerages Expect Merck & Co., Inc. (MRK) Will Post Earnings of $0.87 Per Share - May 15 at 10:06 AM



Merck & Co. (MRK) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff